GENCOV研究中入组参与者COVID-19疫苗反应原性分析
GENCOV是一项针对COVID-19阳性成人的前瞻性观察性队列研究,在加拿大安大略省招募554名参与者,通过问卷收集人口学和疫苗接种数据,采用多变量逻辑回归评估疫苗生产商、类型及既往SARS-CoV-2感染与反应原性的关联。结果显示疲劳和局部副作用最常见,多数在1-2天内出现并消退;Moderna mRNA和AstraZeneca载体疫苗接种者报告反应较Pfizer-BioNTech mRNA疫苗更频繁,既往SARS-CoV-2感染与副作用发生独立相关。
要点
- 疲劳和局部副作用是各剂次疫苗最常见反应,多数在1-2天内出现并消退。
- Moderna mRNA和AstraZeneca载体疫苗接种者报告反应较Pfizer-BioNTech mRNA疫苗更频繁。
- 既往SARS-CoV-2感染与副作用发生独立相关。
核心结论
- 已接种获批COVID-19疫苗的参与者报告的反应相对轻微且短暂。
研究设计与样本
- 前瞻性观察性队列研究,在加拿大安大略省招募COVID-19阳性成人,共获得554名参与者的问卷回答。
主要发现
- 疲劳和局部副作用是各疫苗剂次中最常见反应。
- 多数参与者的副作用在1-2天内出现并消退。
- Moderna mRNA和AstraZeneca载体疫苗接种者报告反应较Pfizer-BioNTech mRNA疫苗接种者更频繁。
- 既往SARS-CoV-2感染与发生副作用独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. METHODS: Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity. RESULTS: Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1-2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects. CONCLUSIONS: We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.
引用
- Morgan G, Casalino S, Chowdhary S, et al. COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study. Vaccine. 2024. PMID: 38521677. doi:10.1016/j.vaccine.2024.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。